--------------------
- Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest. doi link

Auteur(s): Lobo João, Cardoso Ana rita, Miranda-gonçalves Vera, Looijenga Leendert h j, Lopez M., Arimondo Paola b, Henrique Rui, Jerónimo Carmen(Corresp.)

(Article) Publié: Pharmaceutics, vol. 13 p.https://www.ncbi.nlm.nih.gov/pubmed/33430420 (2021)


PMID 33430420
DOI: 10.3390/pharmaceutics13010073
Résumé:

Less toxic treatment strategies for testicular germ cell tumor (TGCT) patients are needed, as overtreatment is a concern due to the long-term side effects of platin-based chemotherapy. Although clinical benefit from classical hypomethylating agents has to date been limited, TGCTs show an abnormal DNA methylome indicating the potential of treating TGCTs with hypomethylating drugs. We tested, for the first time in TGCT cell lines, a new synthetic flavonoid compound (MLo1302) from the 3-nitroflavanone family of DNA methyltransferase (DNMT) inhibitors. We show that MLo1302 reduces cell viability (including of cisplatin resistant cell line NCCIT-R), with IC